ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Vasculitis"

  • Abstract Number: 2791 • 2019 ACR/ARP Annual Meeting

    Treatment Response Criteria for Anti-neutrophil Cytoplasmic Antibodies (ANCA)-vasculitis: Results of a Scoping Review

    Sara Monti1, Kaitlin Quinn 2, Robin Christensen 3, Alfred Mahr 4, Christian Pagnoux 5, Carol Langford 6, David Jayne 7, Peter Merkel 8 and Gunnar Tomasson 9, 1University of Pavia, Pavia, Italy, 2Georgetown University Hospital/National Institutes of Health, Washington, DC, 3Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital & Department of Rheumatology, Institute of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark, 4Hospital Saint-Louis, University Paris Diderot, Paris, France, 5Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, 6Cleveland Clinic, Cleveland, OH, 7Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, UK, Cambridge, United Kingdom, 8University of Pennsylvania, Philadelphia, PA, 9Faculty of Medicine, University of Iceland and Landpitali University Hospital, Reykjavik, Iceland

    Background/Purpose: A comprehensive assessment of outcome measures to assess response to treatment in ANCA-associated vasculitis (AAV) is necessary to implement.Methods: We performed a scoping review…
  • Abstract Number: 1666 • 2019 ACR/ARP Annual Meeting

    Maintenance Treatment in ANCA Associated Vasculitis in Real World Clinical Practice – Burden of Disease, Use of Glucocorticoids and Impact on Patient Functional Status Remain Major Problems

    Dieter Goette1 and Peter Rutherford 1, 1Vifor Pharma, Zurich, Zurich, Switzerland

    Background/Purpose: After successful remission induction AAV is a relapsing remitting long term condition and patients are at risk of organ damage from both active AAV…
  • Abstract Number: 1745 • 2019 ACR/ARP Annual Meeting

    Exercise Improves Arterial Inflammation in Childhood-onset Takayasu Arteritis: A Randomized Controlled Trial

    Camilla Astley1, Gleice Clemente 2, Maria Teresa Terreri 3, Camila Carneiro 4, Marcos lima 4, Carlos Buchpiguel 4, Hilton Leão Filho 4, Fernanda Lima 1, Ana Lúcia Sá-Pinto 1, Clovis Silva 5, Nadia Aikawa 6, Saulo Gil 1, Hamilton Roschel 1, Rosa Pereira 7 and Bruno Gualano 1, 1Division of Rheumatology, Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, sao paulo, Sao Paulo, Brazil, 2ivision of Paediatric Rheumatology, Departament of Paediatrics, Universidade Federal de São Paulo, sao paulo, Sao Paulo, Brazil, 3Pediatric Rheumatology Unit, Universidade Federal de São Paulo, São Paulo, Brazil, 4Nuclear Medicine Institute, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, sao paulo, Sao Paulo, Brazil, 5Pediatric Rheumatology Unit, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Brazil, 6Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Brazil, 7Faculdade de Medicina da Universidade de Sao Paulo, São Paulo, Sao Paulo, Brazil

    Background/Purpose: Childhood-onset Takayasu Arteritis (c-TA) is a rare primary systemic vasculitis that affects aorta and its major branches. This condition is associated with reduced wall…
  • Abstract Number: 2918 • 2019 ACR/ARP Annual Meeting

    Metabolic Signatures of Pathogenic T Cells in Medium and Large Vessel Vasculitis

    Mitsuhiro Akiyama 1, Hui Zhang 1, Ryu Watanabe 1, Toshihisa Maeda 2, Gerald Berry 1, Jorg Goronzy 1 and Cornelia Weyand1, 1Stanford University, Stanford, CA, 2Matsubara Mayflower Hospital, Kobe, Japan

    Background/Purpose: Giant cell arteritis (GCA) is an autoimmune vasculitis that causes aortic arch syndrome, blindnesss, and stroke. Embedded in granulomatous infiltrates, CD4 T cells persist…
  • Abstract Number: 1667 • 2019 ACR/ARP Annual Meeting

    Long Term Outcome of Hydralazine-Associated Vasculitis

    Saja Almaaitah1, Kinanah Yaseen 2, Yuxuan Jin 3 and Rula Hajj-ali 4, 1Internal Medicine Residency/Cleveland Clinic, University Heights, OH, 2Cleveland Clinic, Cleveland, OH, 3Quantitative Health Science, Cleveland Clinic, Cleveland, OH, 4Rheumatologic and Immunologic Disease/Cleveland Clinic, Cleveland, OH

    Background/Purpose: Hydralazine associated vasculitis (HAV) is rare but with potentially detrimental complications, affecting different organ systems. Most case series described short term disease course. Hence,…
  • Abstract Number: 1747 • 2019 ACR/ARP Annual Meeting

    Practice Variations in Treatment of Pediatric Anti-neutrophil Cytoplasmic Antibody (ANCA)-associated Vasculitis (AAV) with Renal Disease

    Audrea Chen1, Cherry Mammen 1, Jaime Guzman 2, David Cabral 2 and Kimberly Morishita 1, 1BC Children's Hospital, Vancouver, BC, Canada, 2University of British Columbia, Vancouver, BC, Canada

    Background/Purpose: Renal disease is common in ANCA-associated vasculitis (AAV) and one of the goals of early treatment is to maximize renal function recovery. Corticosteroids are…
  • Abstract Number: 1670 • 2019 ACR/ARP Annual Meeting

    Evaluation of Subclinical Coronary Atherosclerosis in ANCA-associated Small Vessel Vasculitides (AAVs) Compared to Matched Controls Through Visual Assessment of Coronary Arterial Calcium (CAC) Score Using Non-Gated Chest Computed Tomography (CT)

    Sohail Farshad1, Alexandra Halalau 2, Sayf Al-Katib 3, Julie George 4 and Elena Schiopu 5, 1Department of Internal Medicine, Beaumont Health System, Royal Oak, MI, 2Department of Internal Medicine, Beaumont Health System, Royal Oak, 3Department of Radiology, Beaumont Health System, Royal Oak, MI, 4Beaumont Health System, Royal Oak, MI, 5Department of Rheumatology, University of Michigan, Ann Arbor

    Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) is the most prevalent adult vasculitis and is associated with significant inflammatory burden; chest computed tomography (CT)…
  • Abstract Number: 2104 • 2019 ACR/ARP Annual Meeting

    Vasculitis in HIV-Infected Individuals: Making the Case for an Antigen Driven Process

    Courtney McCray1, Gloria Salazar 2, Ryan Valicek 1, Binh Nguyen 3, Benjamin Naovarat 4, Francis Williams 2 and John Reveille 2, 1University of Texas McGovern Medical School, Houston, TX, 2University of Texas McGovern Medical School, Houston, 3University of Texas McGoven Medical School, Houston, 4University of Texas-McGovern Medical School, Houston, TX

    Background/Purpose: A large spectrum of vasculitides affecting small, medium, and large vessels have been reported in HIV-infected individuals. Although vasculitis is a rare manifestation of…
  • Abstract Number: 1671 • 2019 ACR/ARP Annual Meeting

    Hospital Admissions and Mortality in Patients with ANCA-associated Vasculitis

    Jon Golenbiewski1, Amanda Eudy 2, Megan Clowse 2 and Nancy Allen 2, 1Duke University, Durham, NC, 2Duke University, Durham

    Background/Purpose: ANCA-associated vasculitis (AAV) has a high rate of complications, both from disease itself and treatments. Hospital mortality rates for AAV range between 10-20%. There…
  • Abstract Number: 2281 • 2019 ACR/ARP Annual Meeting

    The Vasculitis Pregnancy Registry (V-PREG): Information from the First 3 Years

    Jon Golenbiewski1, Kalen Young 2, Cristina Burroughs 3, Joyce Kullman 2, Peter Merkel 4 and Megan Clowse 5, 1Duke University Medical Center, Durham, NC, 2Vasculitis Foundation, Kansas City, MO, 3University of South Florida, Tampa, FL, 4University of Pennsylvania, Philadelphia, PA, 5Duke University, Durham

    Background/Purpose: As outcomes for patients with vasculitis improve and treatments become less ovarian-toxic, more women with these diseases will become pregnant. How best to manage…
  • Abstract Number: 1675 • 2019 ACR/ARP Annual Meeting

    A Retrospective Cohort Study Using Clinical Notes and Latent Topic Modeling to Characterize the Natural History of ANCA-Associated Vasculitis

    Liqin Wang1, Eli Miloslavsky 2, John Stone 3, Hyon K. Choi 4, Li Zhou 5 and Zachary Wallace 2, 1Brigham and Women's Hospital, Boston, 2Massachusetts General Hospital, Boston, 3Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, 4Massachusetts General Hospital, Boston, MA, 5Brigham and Women's Hospital, Boston, MA

    Background/Purpose: ANCA-associated vasculitis (AAV) is associated with end-organ damage, complications of treatment, and excess death.  Retrospective studies on the clinical course of AAV, including the…
  • Abstract Number: 2620 • 2019 ACR/ARP Annual Meeting

    Effects of Tofacitinib Suppressed Pulmonary Vascular Remodeling of Allergic Vasculitis in a Murine Model

    Yuka Oikawa1, Kohei Yamauchi 2 and Makoto Maemondo 1, 1Iwate Medical University School of Medicine, Morioka, Japan, Division of Pulmonary medicine, Allergy and Rheumatology, Department of Internal Medicine, morioka, Japan, 2Takizawa central Hospital, morioka, Japan

    Background/Purpose: We reported allergic granulomatous vasculitis with eosinophil infiltration in an asthma model of C57BL/6 sensitized with ovalbumin (OVA). TGF-btea and IL-6 are thought to…
  • Abstract Number: 1677 • 2019 ACR/ARP Annual Meeting

    Management of Severe Renal Disease in Anti-Neutrophil-Cytoplasmic-Antibodies Associated Vasculitis: Role of Rituximab and Plasma Exchange?

    Pauline Morel 1, Alexandre Karras 2, Raphael Porcher 3, Xavier Belenfant 4, Vincent Audard 5, Cédric Rafat 6, Guillaume Hanouna 7, Séverine Beaudreuil 8, Cédric Vilain 9, Aurélie Hummel 10, Benjamin Terrier 11, Evangeline Pillebout 12, Matthieu Groh 13, Romain Jouenne 14, Robin Dhote 15, Olivier Fain 16, Matthieu Ponsoye 17, Nicolas Noel 18, Nicolas Limal 19, Loïc Guillevin 11, Luc Mouthon 11 and Alexis Régent11, 1Cochin Hospital, Paris, France, 2Paris HEGP, Paris, France, 3Hotel Dieu Hospital, Paris, France, 4Service de néphrologie, Hôpital André Grégoire, 56 Boulevard de la Boissière Montreuil, France, Montreuil, Ile-de-France, France, 5Henri Mondor Hospital, Créteil, France, 6Tenon Hospital, Paris, France, 7Service de néphrologie, Hôpital Bichat-Claude Bernard, AP-HP, 46 rue Henri Huchard, Paris, France., Paris, Ile-de-France, France, 8Bicetre Hospital, Le Kremlin Bicetre, France, 9Service de néphrologie hémodialyse, Hôpital Ambroise Paré, APHP, 9 avenue Charles de Gaulle, Boulogne-Billancourt, France, Boulogne-Billancourt, Ile-de-France, France, 10APHP, Paris, France, 11National Referral Center for Rare Systemic Autoimmune Diseases Paris Cochin, Paris, France, 12Service de néphrologie et transplantation, Hôpital Saint-Louis, AP-HP, 1 avenue Claude Vellefaux, Paris, France., Paris, Ile-de-France, France, 13Service de médecine interne, maladies systémiques, Hôpital Saint Louis, AP-HP, 1 avenue Claude Vellefaux, Paris, France, Paris, Ile-de-France, France, 14Service de médecine interne, Hôpital Bichat-Claude Bernard, AP-HP, 46 rue Henri Huchard, Paris, France, Paris, Ile-de-France, France, 15Service de médecine interne, Hôpital Avicenne, AP-PH, 125 rue de Stalingrad, Bobigny, France, Bobigny, Ile-de-France, France, 16Service de médecine interne, Hôpital Saint-Antoine, AP-HP, 184 rue du Faubourg Saint-Antoine, Paris, France, Paris, Ile-de-France, France, 17Service de médecine interne, Hopital Ambroise Paré, Boulogne-Billancourt, Boulogne-Billancourt, Ile-de-France, France, 18Service de médecine interne et immunologie clinique, Hôpital Bicêtre, AP-HP, 78 rue du Général Leclerc, Kremlin-Bicêtre, France, Kremil-Bicêtre, Ile-de-France, France, 19Service de médecine interne, Hôpital Henri-Mondor, AP-HP, 51 Avenue du Maréchal de Lattre de Tassigny, Créteil, France, Créteil, Ile-de-France, France

    Background/Purpose: Induction therapy for severe ANCA-associated vasculitides (AAVs) is based on the combination of glucocorticoids and cyclophosphamide (CYC) or rituximab (RTX). For patients with severe…
  • Abstract Number: 2621 • 2019 ACR/ARP Annual Meeting

    Association Between Outcome Renal, Clinical Variables and Findings of Renal Biopsy in Patients with ANCA Vasculitis

    Linda Vergel Orduz1, Alejandro Brigante 2, Diego Marino 3, Natalia Perrotta 3, Romina Hassan 4, Gisele Verna 5, Adriana Hamaui 6, Eduardo Kerzberg 7 and Diana Dubinsky 6, 1Sanatorio Guemes, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, 2Sanatorio Güemes, Servicio de Medicina Interna – Reumatología, Francisco Acuña de Figueroa 1240, C1180AAD, Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, 3Hospital de Clínicas José de San Martín, Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, 4Hospital Ramos Mejía, Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, 5Sanatorio Guemes, Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, 6Sanatorio Güemes, Buenos Aires, Argentina, 7Hospital Ramos Mejia, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina

    Background/Purpose: In associated ANCA vasculitis (AAV), rapidly progressive glomerulonephritis (GN) is one of the most serious complications. In 40% of cases they progress to chronic…
  • Abstract Number: 312 • 2019 ACR/ARP Annual Meeting

    Timely Glucocorticoid Tapering in Vasculitis: A Need for Improved Knowledge Translation to Limit Toxicity

    Arielle Mendel1, Daniel Ennis 2, Shirley Lake 3, Simon Carette 4 and Christian Pagnoux 4, 1Mount Sinai Hospital, Toronto, ON, Canada, 2University of Toronto, Toronto, ON, Canada, 3Division of Rheumatology, Sunnybrook Hospital, Toronto, ON, Canada, 4Mount Sinai Hospital and University Health Network, Toronto, ON, Canada

    Background/Purpose: High dose glucocorticoids (GC) are part of the initial treatment of ANCA-associated (AAV) and large vessel vasculitides (LVV). Prompt subsequent tapering limits toxicity. Adherence…
  • « Previous Page
  • 1
  • …
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology